FDA 483 - Octapharma S.A.S. - December 06, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Octapharma S.A.S. in Lingolsheim, France, a biologics blood product manufacturer, received a Form 483 citing numerous significant deficiencies. The inspection revealed inadequate assessment of product impact from discrepancies, failure to follow written procedures, and insufficient employee training. Critical issues also included poor equipment maintenance, unsuitable building design and repair, pervasive pest infestations, and a lack of data integrity controls, indicating a broad breakdown in cGMP compliance.
ID · 2fed28cf-3657-4dd8-a46d-22ac235f0f62